Fact CheckerSign in

NCT07439159Recruiting

Echocardiography-Based Predictors of Outcomes in Hospitalized Patients With Decompensated Heart Failure (ECHO-DECOMP)

Early Transthoracic Echocardiographic Predictors of Recurrent Hospitalization and Survival in Patients Hospitalized Due to Decompensated Heart Failure

Source: ClinicalTrials.gov · Last updated 27 Feb 2026

Brief summary (registry, in English)

Acute decompensated heart failure is a leading cause of hospitalization and is associated with high morbidity and mortality. Early risk stratification in this population is crucial for guiding treatment strategies and predicting short- and long-term clinical outcomes. Transthoracic echocardiography is routinely performed in patients hospitalized with acute decompensated heart failure and provides comprehensive information regarding cardiac structure and function. However, the prognostic value of detailed echocardiographic parameters obtained before the initiation of intravenous diuretic therapy has not been fully clarified. The objective of this prospective study is to evaluate the prognostic significance of transthoracic echocardiographic findings obtained at hospital admission, prior to intravenous diuretic therapy, in patients hospitalized with acute decompensated heart failure. The study will assess key echocardiographic parameters reflecting left and right heart structure and function, including left ventricular ejection fraction, left ventricular dimensions and geometry, left atrial size and volume, indices of right ventricular systolic function (such as TAPSE, tissue Doppler-derived S' velocity, and fractional area change), pulmonary artery systolic pressure, right ventricular-pulmonary artery coupling assessed by the TAPSE/PASP ratio, and right ventricular outflow tract acceleration time. Primary outcome measures include in-hospital mortality, post-discharge mortality, myocardial infarction, ischemic stroke, and heart failure-related rehospitalization. Secondary outcomes include the need for non-invasive or invasive mechanical ventilation during hospitalization, requirement for inotropic support, changes in B-type natriuretic peptide levels, development of acute kidney injury, and occurrence of new-onset cardiac arrhythmias. By prospectively evaluating echocardiographic parameters and their associations with clinical outcomes, this study aims to clarify the prognostic role of early echocardiographic assessment in acute decompensated heart failure and to contribute to improved risk stratification and clinical decision-making in this high-risk population.

Status (registry)
Recruiting
Study type
Observational
Enrollment
76 (estimated)
First submitted
18 Jan 2026
Start date
3 Mar 2024
Primary completion date
31 Aug 2026
Lead sponsor
Istanbul University - Cerrahpasa
NCT number
NCT07439159

What you commit to

  • Study type: Observational
  • Planned participants: 76
  • From 3 Mar 2024 to the primary completion date, 31 Aug 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Requirement for renal replacement therapy, including hemodialysis or peritoneal dialysis, or being listed for kidney transplantation.
  • Inability to perform transthoracic echocardiography prior to intravenous diuretic therapy for any reason.

Other illness

  • Primary right heart failure.
  • Heart failure secondary to congenital heart disease.
  • History of mitral valve replacement.
  • History of aortic valve replacement.
  • History of bioprosthetic valve replacement.
  • History of transcatheter aortic valve implantation.
  • Presence of active malignancy.
  • Failure to provide written informed consent.

Lab values

  • Severe anemia (hemoglobin \<7 g/dL).

Other

  • Severe primary mitral regurgitation.
  • Severe aortic stenosis.
  • Severe aortic regurgitation.
  • Severe primary tricuspid regurgitation.

Who the study is looking for

  • Adults aged ≥18 years.
  • Hospitalization due to acute decompensated heart failure.
  • Intravenous diuretic therapy deemed necessary by the treating cardiologist.
  • Predominant left-sided heart failure.
  • Provision of written informed consent prior to participation.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Istanbul University Cerrahpaşa Institute of Cardiology
Coordinator of this site? Confirm its status
IstanbulTurkey (Türkiye)Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.